Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer

worldpharmanewsSeptember 05, 2019

Tag: Tagrisso , EGFR , Cancer , AstraZeneca , Lung

PharmaSources Customer Service